The company has informed NICE that it will not be providing an evidence submission for this appraisal at the current time. Therefore, the appraisal has been suspended. NICE will continue to monitor the situation and provide an update as and when the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3858 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 July 2024 | Expected publication |
| 16 May 2023 | Suspended. The company has informed NICE that it will not be providing an evidence submission for this appraisal at the current time. Therefore, the appraisal has been suspended. NICE will continue to monitor the situation and provide an update as and when the situation changes. |
| 19 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in late August 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late October 2023. |
| 06 July 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-June 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 01 April 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission |
For further information on our processes and methods, please see our CHTE processes and methods manual